Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos

Y. L. Wu, D. Planchard, S. Lu, H. Sun, N. Yamamoto, D. W. Kim, D. S.W. Tan, J. C.H. Yang, M. Azrif, T. Mitsudomi, K. Park, R. A. Soo, J. W.C. Chang, A. Alip, S. Peters, J. Y. Douillard

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

Original languageEnglish
Pages (from-to)171-210
Number of pages40
JournalAnnals of Oncology
Volume30
Issue number2
DOIs
StatePublished - 1 Feb 2019

Fingerprint

Medical Oncology
Practice Management
Practice Guidelines
Non-Small Cell Lung Carcinoma
Guidelines
China
Group Processes
Malaysia
Singapore
Expert Testimony
Politics
Therapeutics
Korea
Taiwan
Consensus
Japan
Thorax
Pharmaceutical Preparations
Neoplasms

Keywords

  • Consensus
  • Guidelines
  • Metastatic NSCLC
  • Pan-asian

Cite this

Wu, Y. L. ; Planchard, D. ; Lu, S. ; Sun, H. ; Yamamoto, N. ; Kim, D. W. ; Tan, D. S.W. ; Yang, J. C.H. ; Azrif, M. ; Mitsudomi, T. ; Park, K. ; Soo, R. A. ; Chang, J. W.C. ; Alip, A. ; Peters, S. ; Douillard, J. Y. / Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer : A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos. In: Annals of Oncology. 2019 ; Vol. 30, No. 2. pp. 171-210.
@article{c5e12b0c43b24680a8b5901507f9a822,
title = "Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos",
abstract = "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.",
keywords = "Consensus, Guidelines, Metastatic NSCLC, Pan-asian",
author = "Wu, {Y. L.} and D. Planchard and S. Lu and H. Sun and N. Yamamoto and Kim, {D. W.} and Tan, {D. S.W.} and Yang, {J. C.H.} and M. Azrif and T. Mitsudomi and K. Park and Soo, {R. A.} and Chang, {J. W.C.} and A. Alip and S. Peters and Douillard, {J. Y.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/annonc/mdy554",
language = "English",
volume = "30",
pages = "171--210",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

Wu, YL, Planchard, D, Lu, S, Sun, H, Yamamoto, N, Kim, DW, Tan, DSW, Yang, JCH, Azrif, M, Mitsudomi, T, Park, K, Soo, RA, Chang, JWC, Alip, A, Peters, S & Douillard, JY 2019, 'Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos', Annals of Oncology, vol. 30, no. 2, pp. 171-210. https://doi.org/10.1093/annonc/mdy554

Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer : A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos. / Wu, Y. L.; Planchard, D.; Lu, S.; Sun, H.; Yamamoto, N.; Kim, D. W.; Tan, D. S.W.; Yang, J. C.H.; Azrif, M.; Mitsudomi, T.; Park, K.; Soo, R. A.; Chang, J. W.C.; Alip, A.; Peters, S.; Douillard, J. Y.

In: Annals of Oncology, Vol. 30, No. 2, 01.02.2019, p. 171-210.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer

T2 - A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos

AU - Wu, Y. L.

AU - Planchard, D.

AU - Lu, S.

AU - Sun, H.

AU - Yamamoto, N.

AU - Kim, D. W.

AU - Tan, D. S.W.

AU - Yang, J. C.H.

AU - Azrif, M.

AU - Mitsudomi, T.

AU - Park, K.

AU - Soo, R. A.

AU - Chang, J. W.C.

AU - Alip, A.

AU - Peters, S.

AU - Douillard, J. Y.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

AB - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

KW - Consensus

KW - Guidelines

KW - Metastatic NSCLC

KW - Pan-asian

UR - http://www.scopus.com/inward/record.url?scp=85061194290&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy554

DO - 10.1093/annonc/mdy554

M3 - Review article

C2 - 30596843

AN - SCOPUS:85061194290

VL - 30

SP - 171

EP - 210

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -